Cannabinoids receptors: popular preclinical target but banned in 137 countries
Pharmaceutical Technology
DECEMBER 5, 2022
Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. Despite the current popularity of cannabinoid receptors, the regulatory landscape is challenging and complex. This is closely followed by CB2 receptors in second place.
Let's personalize your content